Community Based Medications First for Opioid Use Disorder- Care utilization and mortality outcomes

Caleb J. Banta-Green PhD MSW MPH ¹²³, Mandy D. Owens PhD ¹, Jason R. Williams PhD ¹, Jeanne M. Sears PhD RN ²³⁴, Anthony S. Floyd PhD ¹, Wendy Williams-Gilbert PhD RN ⁵, Susan Kingston ¹ 1 Addictions, Drug & Alcohol Institute, Dept of Psychiatry and Behavioral Sciences, School of Public Health, School of Public Health, University of Washington Seattle, WA, USA 3 Harborview Injury Prevention and Research Center University of Washington Seattle, WA, USA 4 Institute for Work and Health, Toronto, Ontario, Canada 5 Southern New Hampshire University, Manchester, NH, USA

BACKGROUND AND AIMS

A large treatment gap exists for people with opioid use disorder (OUD) receiving medications for opioid use disorder (MOUD) which are the most effective evidencebased treatments. Most people with OUD want to stop/reduce their use and are interested in MOUD¹. Many access services in harm reduction and other community-based organizations and have had difficulty starting or engaging in care at treatment centers of primary care offices. We previously implemented and tested a low-barrier buprenorphine clinic at a Seattle syringe services program (SSP), utilizing a nurse care manager model, that was feasible with positive intermediate outcomes². This study adapts that model by adding care navigators and implementing it in multiple, diverse sites across WA State.

Our primary aim tests the impact of the intervention on morbidity and mortality outcomes. Other aims test if housing status modifies the impact of the intervention and the impact of the intervention on MOUD utilization.

CLINICAL INTERVENTION AND SETTINGS

The Community Based Medication-First (CBMF) *intervention* is based upon rapid, typically same-day, access to medications; convenient, non-appointment based care; no exclusions for poly-substance use; no counseling mandates (but services readily available); and ongoing, easy to access care. The model is intended for people who may have barriers to appointment-based care, including those who are unhoused. Staffing for Community-Based Mediation-First (CBMF) was based upon project-funded care teams comprised of a nurse care manager and care navigators, as well as a prescriber's time to oversee clinical activities.

All clinics began with drop-in, same-day visits (no appointment required) with workflows designed to provide same-day medication starts when medically appropriate and desired by clients. CBMF staff were often co-located at SSPs to facilitate linkage.

The study's clinical intervention support team provided initial training and ongoing, twice-monthly and ad hoc technical assistance and clinical consultation for nurse care managers and care navigators. Clinical support was provided to prescribers in monthly calls. Site administrators met with the team twice monthly to discuss administrative, clinical, and research issues.

Clinical/Research settings: The goal of this project is to provide care where people with OUD already receive other services and often have established trusting relationships with staff and volunteers. Settings included existing SSP's and other programs providing social and health services for marginalized and unhoused people. The six sites were purposefully selected to represent different types of organizations and geographic variability. Three of the sites were in Eastern Washington (Spokane, Walla Walla, Kennewick) and three in Western Washington (Tacoma, Seattle, Centralia).

METHODS

Our findings indicate a statistically and clinically significant increase in medications for OUD Study participants People with opioid use disorder, per clinician judgment, who were interested in starting on after receiving CBMF and a significant decrease in mortality relative to the comparison group. an FDA approved medication for OUD were eligible for the study if they were: between the ages of 18-70 and Our goal was to provide services to housing-insecure people and 40% of participants studied willing to provide access to state records data. Potential participants were approached about study were housing insecure and unhoused participants also had a substantial and statistically involvement *after* their initial CBMF service encounter. The clinical intervention was implemented, and study significant increase in time on medications. We did not see a change in ED poisoning visits, but it recruitment and enrollment began August 2019. The last month of new clients beginning the 6-month clinical is important to note that the rate of these recorded visits is very low and that previous research intervention was September 2021. 12 months of follow-up data from the date of beginning the clinical indicates that many people who have an overdose do not seek medical care. Not seeking care for intervention was utilized. an overdose was perhaps even more likely given the high rates of naloxone availability in the <u>Study Design & Analyses</u> A prospective cohort study was conducted to test the impacts of the intervention on community (approximately 80% per local SSP surveys) and the reluctance of people to go to the MOUD and care utilization. A synthetic comparison group analysis, based upon a statistically matched from ED during COVID. Conversely, there was a significant increase in inpatient hospitalizations which WA State agency administrative data sources, was conducted to test the impact of the intervention on does not align with ED poisoning findings and may be related to care utilization for COVID. mortality. Descriptive statistics are presented. Pre-post comparison of rates of care utilization based on days supply of buprenorphine or number of months with an event was tested with an unadjusted model *Limitations* We know that SARS-CoV-2 precautions severely limited clinical visit time which regressing change score on housing status. The all-cause mortality rate difference between the intervention decreased study enrollment opportunities. Many sites needed to switch from drop-in care to and comparison group was tested in a logistic regression model accounting for propensity score weighting appointments for initial and ongoing care, potentially decreasing ongoing service utilization and and included history variables used in estimating the propensity score as covariates, followed by marginal study enrollment. effects estimation to calculate an average risk ratio. In the first stage of creating a comparison group, In preparing for this study we estimated an annual mortality rate of 6% for those with opioid use members of the large de-identified comparison pool with an indication of OUD were assigned the treatment seen for care in the ED, based on a Seattle study³ as well as very similar findings in group member's start date and matched on key broad indicators of OUD history. In the second stage, Massachusetts⁴. In this study the matched comparison, which had an extensive history of propensity score matching was implemented with more fine-grained history variables to match and balance medication use for OUD, had a lower mortality rate than we anticipated, and yet the intervention the samples. group still had a significantly reduced mortality rate.

RESULTS

1,325 people received the CMBF clinical intervention. 825 people enrolled in the study and 813 were matched to state records. CBMF service recipients had similar age and gender as those enrolled in the study and those with complete Medicaid data Table 1). Those with complete Medicaid eligibility were similar to all enrolled in the CBMF study except they had higher rates for care measures. Those with complete eligibility for Medicaid had lower rates of arrest, likely due in part losing Medicaid eligibility while incarcerated. Those with complete Medicaid data had a somewhat smaller proportion who were unstably housed.

Table 1- Participant characteristics atbaseline and utilization prior 12 months	All clients served	Enrolled and matched to state data	Complete Medicaid data 463		
n=	1,325	813			
Demographics					
Age- mean		36.85	37.78		
<20	2.1%	0.6%	0.4%		
20-29	24.9%	27.4%	25.3%		
30-39	36.6%	37.9%	36.7%		
40-49	18.8%	20.5%	21.4%		
50-59	10.0%	9.7%	12.1%		
60+	4.5%	3.8%	4.1%		
missing	3.0%	0.0%	0.0%		
Female	41%	40%	49%		
Unstably/un-housed		44.1%	40.6%		
Medications for opioid use disorder utilization					
Buprenorphine – days supply		32.0	42.8		
Buprenorphine - any		52.3%	58.8%		
Buprenorphine - months with		2.35	3.02		
Methadone - any		6.03%	8.21%		
Methadone - months with		0.27	0.38		
Naltrexone - any		2.8%	3.2%		
Naltrexone - months with		0.071	0.08		
Any OUD medication - months with		2.66	3.43		
Any OUD medication		56.0%	63.7%		
Arrests					
Arrests % any		40.0%	34.6%		
Arrests month with		0.91	0.71		
Emergency Department and Inpatient Hospital	Utilization				
ED Poisoning - any		3.8%	4.1%		
ED poisoning - months with		0.044	0.045		
ED non-poisoning - any		54.7%	65.0%		
ED non-poisoning - months with		1.42	1.71		
Hospitalization - any		25.7%	30.0%		
Hospitalization- months with		0.48	0.57		







<u>Characteristics of clients served and analytic sub-groups</u>

1.McMahan VM, Kingston S, Newman A, Stekler JD, Glick SN, Banta-Green CJ. Interest in reducing methamphetamine and opioid use among syringe services program participants in Washington State. Drug Alcohol Depend. 2020 Nov 1;216:108243. doi: 10.1016/j.drugalcdep.2020.108243. Epub 2020 Aug 23. PMID: 32911134; PMCID: PMC9632690. 2.Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, Glick SN, Hamblin M, Holcomb S, Mosse D, Oliphant-Wells T, Shim MM. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington. Subst Abus. 2020;41(3):356-364. doi: 10.1080/08897077.2019.1635557. Epub 2019 Aug 12. PMID: 31403907. 3. Banta-Green CJ, Coffin PO, Merrill JO, Sears JM, Dunn C, Floyd AS, Whiteside LK, Yanez ND, Donovan DM. Impacts of an opioid overdose prevention intervention delivered subsequent to acute care. Inj Prev. 2019 Jun;25(3):191-198. doi: 10.1136/injuryprev-2017-042676. Epub 2018 Feb 7. PMID: 29436397; PMCID: PMC6800078. 4. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Ann Intern Med. 2018 Aug 7;169(3):137-145. doi: 10.7326/M17-3107. Epub 2018 Jun 19. PMID: 29913516; PMCID: PMC6387681

DISCUSSION & CONCLUSION

<u>Impact of CBMF on medications for OUD and health care utilization</u>

Care utilization outcome analyses were restricted analyses to those with complete Medicaid eligibility in the 12 months prior to and following receiving CBMF. Table 2 compares the year before and after starting CBMF.

Table 2. Changes pre-post among intervention participants n=		gible ⁺ housing data		Stably housed at baseline 265		Unstably housed at baseline 181		Change by housing status				
	Pre	Post	Pre	Post	p<0.05	Pre	Post	p<0.05	Pre	Post	p<0.05	p<0.05
Medications for opioid use disorder utilizat	ion											
Buprenorphine days supply	42.76	107.85	43.64	111.02	*	45.18	121.27	*	41.38	96.02	*	*
OUD medication- months with any	3.43	7.07	3.47	7.15	*	3.42	7.55	*	3.54	6.57	*	*
Buprenorphine- months with any	3.02	6.35	3.06	6.46	*	3.08	6.95	*	3.03	5.75	*	*
Acute care utilization												
ED poisoning visit- months with any	0.05	0.04	0.05	0.04		0.02	0.03		0.08	0.07		
ED non-poisoning visit- months with any	1.71	1.60	1.71	1.60		1.51	1.45		2.00	1.81		
Any hospital stay- months with any	0.57	1.63	0.59	1.65	*	0.53	1.65	*	0.67	1.65	*	


*Noted as Medicaid eligible in all 12 months before and after the start month

• Days supply of buprenorphine, Months with any OUD medication, and Months with any buprenorphine all increased significantly overall and for both housed and unhoused people. Those who were housed had a significantly greater increase compared to those who were unhoused.

- Both Months with and without an ED poisoning did not change overall, nor by housing status. • Months with an inpatient stay increased significantly overall, but did not differ significantly by housing status.
- Among those who had any buprenorphine in the pre-period (n=243) the change in buprenorphine days supply and increased significantly from a mean of 81.5 days to 136.5 days (p<0.05). (data not shown)

Mortality analyses

Using a different analytic approach for mortality analyses, we used a matched comparison group drawn from state records data. For the matched comparison analyses, intervention participants were included if they had an indication of a history of OUD based upon the presence of an OUD or opioid poisoning diagnosis and/or a previous indication of having received a medication for the treatment of OUD. The comparison group was matched based upon multiple variables including geography, demographics, care utilization, and arrest history. The observed annual death rate in the first year for the intervention group was 0.45% (3 out of 664) compared to 2.2% (222 out of 9893) in the comparison group in the 12 months; a relative risk of 0.323 (95% CI 0.11-0.94) p-value = 0.039. This can be interpreted as the CBMF intervention has a significant impact on reducing mortality with an estimated 68% reduction (95% CI 6%-89%) relative to the comparison group.



Funding for this research was provided by the Paul G. Allen Family Foundation which had no role in the design of the study and collection, analysis, and interpretation of data. The authors declare that they have no The University of Washington IRB determined that the application qualified for expedited review and approved it (IRB ID# STUDY00006623). The WA State IRB reviewed and approved the use of state-held secondary data records and (Project # 2019-032).